冠心病合并缺血性二尖瓣反流:CABG联合瓣膜修复与置换的生存比较
基于Medicare索赔数据,纳入10471例接受CABG联合二尖瓣修复/瓣环成形(MVr)或置换(MVR)的缺血性二尖瓣反流患者。
要点
- 观察性获益可能源于未测量混杂因素,如瓣膜病理和反流严重程度。
核心结论
- 在Medicare缺血性二尖瓣反流患者中,风险调整后CABG/MVr与较CABG/MVR更长的生存相关。
- 以外科医生偏好为工具变量后,偏好MVr或MVR的外科医生所治患者长期生存相似。
- 观察到的MVr生存优势可能由未测量混杂因素(如瓣膜病理和反流严重程度)解释。
研究设计与样本
- 回顾性队列研究,使用Medicare索赔数据识别接受CABG/MVr或CABG/MVR的缺血性二尖瓣反流受益人。
- 共纳入10471例受益人,其中6457例(61.7%)接受CABG/MVr,4014例(38.3%)接受CABG/MVR。
- 采用Kaplan-Meier法估计生存,比较20年限制性平均生存时间(RMST),并使用重叠倾向评分加权进行风险调整。
- 将1118名外科医生按CABG/MVr率分层为偏好MVr组(PA,223名,MVr率89.5%)和偏好MVR组(PR,235名,MVr率23.0%),按外科医生偏好重新分析结局。
临床怎么用
- 对于接受CABG联合二尖瓣手术的缺血性二尖瓣反流患者,选择MVr或MVR应综合考虑瓣膜病理和反流严重程度等个体因素。
- 外科医生偏好分析提示,在充分校正未测量混杂后,MVr与MVR的长期生存可能相当,不宜仅凭观察性生存优势强制选择MVr。
局限性
- 回顾性研究设计,可能存在未测量混杂因素影响治疗选择。
- 使用外科医生偏好作为工具变量仍可能无法完全控制所有混杂。
- 基于Medicare索赔数据,缺乏详细临床变量如瓣膜病理和反流严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retrospective studies of patients with ischemic mitral regurgitation (iMR) undergoing coronary artery bypass grafting (CABG) with concomitant mitral valve surgery frequently report improved survival with mitral valve repair/annuloplasty (MVr) over replacement (MVR). However, the only randomized controlled trial found no survival difference. METHODS: Medicare claims data were queried to identify beneficiaries with iMR undergoing CABG/MVr or CABG/MVR. Kaplan-Meier estimates of survival after CABG/MVr and CABG/MVR were generated, and 20-year restricted mean survival times (RMSTs) were compared. Then, surgeons were stratified by their rate of CABG/MVr into groups with a demonstrated preference for MVr (PA) or MVR (PR). Outcomes were reanalyzed by surgeon preference. Overlap propensity score weighting was used for risk adjustment in all analyses. RESULTS: Among 10,471 beneficiaries with iMR, 6457 (61.7%) underwent CABG/MVr and 4014 (38.3%) underwent CABG/MVR. Risk-adjusted RMSTs were 6.02 years (95% CI, 5.77-6.26 years) after CABG/MVr and 5.57 years (95% CI, 5.33-5.81 years) after CABG/MVR (difference, 5.4 months; 95% CI, 1.2-9.4 months; P = .01). Among 1118 surgeons, 223 were PA surgeons (performed 2191 operations; 89.5% MVr rate) and 235 were PR surgeons (performed 1930 operations; 23.0% MVr rate). Risk-adjusted RMSTs were 5.76 years (95% CI, 5.36-6.15 years) vs 5.77 years (95% CI, 5.40-6.14 years) among beneficiaries undergoing surgery by PA surgeons and PR surgeons, respectively (difference, 0.1 years; 95% CI, -6.6 to 6.6 months, P = .964). CONCLUSIONS: In Medicare beneficiaries with iMR undergoing CABG/mitral valve surgery, CABG/MVr was associated with improved survival, even after risk adjustment for measured confounders. This may be due to unmeasured confounding variables affecting the decision to perform MVr or MVR, such as valvular pathology and/or severity of regurgitation. After endeavoring to account for unmeasured confounders using surgeon preference as an instrumental variable, surgeons who preferred CABG/MVr or CABG/MVR achieved similar long-term survival for their patients.
引用
- George TJ, Squiers JJ, DiMaio JM, et al. Coronary Artery Bypass Grafting With Mitral Annuloplasty or Replacement for Ischemic Mitral Regurgitation in Medicare Beneficiaries. Ann Thorac Surg. 2025. PMID: 39929332. doi:10.1016/j.athoracsur.2025.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。